Uncategorized Archives

Increasing Access to Biosimilar Act introduced to US House of Representatives

by Bioblast Editor, Naomi Pearce | Mar 3, 2023 | Uncategorized

The ‘Increasing Access to Biosimilar Act of 2023’ (HR 1352) was introduced into the US House of Representatives. The bill, if passed by Congress, would ‘require the Secretary of Health and Human Services to establish a demonstration project to increase access to...

Study finds biosimilar switching policy increased biosimilar use more than new start policies

by Bioblast Editor | Feb 8, 2023 | Uncategorized

A new study published in Arthritis Care and Research found that mandatory switching policies were much more effective at driving biosimilar uptake than new start policies. The study examined 5,884 patients taking infliximab (Johnson & Johnson’s Remicade®,...

Saskatchewan adopts biosimilar switching program for 6th province/territory

by Bioblast Editor | Oct 20, 2022 | Uncategorized

The Saskatchewan Ministry of Health announced the introduction of a biosimilar switching program – the 6th of its kind to be introduced into provinces/territories in Canada. Under the new program, the Saskatchewan Drug Plan will only cover listed biosimilars for new...

Erasca and Eli Lilly sign clinical trial collaboration and supply agreement for Erbitux® (cetuximab)

by Bioblast Editor | Jul 18, 2022 | Biosimilars updates, Uncategorized

Erasca and Eli Lilly announced that they have entered into a clinical trial collaboration and supply agreement for Erbitux® (cetuximab). This agreement will support Erasca’s ongoing Ph I trials evaluating ERAS-601, its SHP2 inhibitor, with cetuximab for the treatment...

Amneal publishes Q1 2022 financial results

by Bioblast Editor | May 4, 2022 | Uncategorized

Amneal published its Q1 2022 financial results, reporting a 1% increase YoY in net revenue. Amneal announced that it plans to expand into high growth areas including biosimilars and injectables.

FDA completes its review of Lannett’s IND for biosimilar insulin glargine

by Bioblast Editor | Jan 21, 2022 | Uncategorized

Lannett announced that the FDA has completed its review of the Investigational New Drug Application for biosimilar insulin glargine. Lannett plans to complete the clinical trials by early 2023, with a potential launch in early 2024.